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ABSTRACT  
Gene therapy for cystic fibrosis (CF) is making encouraging progress into clinical trials. 
However, further improvements in transduction efficiency are desired. To develop a 
novel gene transfer vector that is improved and truly effective for CF gene therapy, a 
simian immunodeficiency virus (SIV) was pseudotyped with envelope proteins from 
Sendai virus (SeV), which is known to efficiently transduce unconditioned airway 
epithelial cells from the apical side. This novel vector was evaluated in mice in vivo 
and in vitro directed towards CF gene therapy. Here we show that a) we can produce 
relevant titres of a SIV vector pseudotyped with SeV envelope proteins for in vivo use, 
b) this vector can transduce the respiratory epithelium of the murine nose in vivo at 
levels that may be relevant for clinical benefit in CF, c) this can be achieved in a single 
formulation, and without the need for preconditioning, d) expression can last for 15 
months, e) readministration is feasible, f) the vector can transduce human air-liquid 
interface cultures and g) functional CFTR chloride channels can be generated in vitro. 
Our data suggest that this lentiviral vector may provide a step change in airway 
transduction efficiency relevant to a clinical programme of gene therapy for CF. 
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INTRODUCTION  
Cystic fibrosis (CF) is a fatal genetic disorder caused by mutations in the cystic 
fibrosis transmembrane conductance regulator (CFTR) gene, one function of which is 
to act as a chloride channel in airway epithelial cells. CF is characterized by recurrent 
chest infections, increased airway secretions, and eventually respiratory failure [1]. 
Whilst symptomatic treatments have successfully increased median survival to 
approximately 36 years, definitive novel therapeutic approaches aimed at the basic 
defect are clearly needed. 
 
Given the propensity of certain viruses for infection of the respiratory tract, CFTR 
gene transfer using these vectors has been extensively studied. However, to date no 
viral vector has met the requirements for clinical use [2]. Three major problems have 
been encountered. Gene transfer efficiency is generally poor, at least in part because 
the respective receptors for the viral vectors appear to be predominantly localized to 
the basolateral surface of the airway epithelium. Secondly, penetration of the 
augmented mucus layer typical of CF is generally poor. Finally, the ability to 
administer viral vectors repeatedly, mandatory for such transient expression systems 
in the treatment of a lifelong disease, is limited. With these limitations in mind, we 
describe a novel vector that is able to circumvent some of the difficulties described 
above. 
 
We have previously described the use of Sendai virus (SeV) vectors for airway gene 
transfer [3, 4]. SeV is a single stranded RNA virus, belongs to the family of 
Paramyxoviridae, and is able to overcome the first two of the above noted difficulties. 
Firstly, gene transfer to the airway epithelium is highly efficient, because the sialic acid 
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and cholesterol receptors needed for transduction are present on the apical surface of 
airway epithelial cells. Further, SeV uses a cytoplasmic expression system, thereby 
removing the limitations imposed by the nuclear membrane. Secondly, whilst mucus 
does act as a partial barrier to SeV-mediated gene transfer, the very high expression 
levels generated allow this limitation to be readily tolerated. However, despite our best 
efforts to date, we have been unable to overcome the third impediment to clinical 
translation, namely repeated application of SeV.  
 
A different solution to this problem would theoretically be provided by transduction of 
progenitor or stem cells, normally used to replenish the airway epithelium. If this was 
feasible, ‘single-hit’ gene therapy with a viral vector might overcome this remaining 
hurdle. However, a significant further issue is the identity and localization of these 
progenitor or stem cells. Existing data suggest the presence of specialized cells, 
whose identity and site varies with progression along the branching of the airways [5]. 
In addition, the ciliated epithelium may be able to renew or repair itself; the lifespan of 
these epithelial cells has historically been estimated to be around 3 months [6], but 
has been extended to 6 months in trachea and 17 months in lung in a most recent 
publication [7]. Irrespective of the appropriate target cell, an integrating vector would 
clearly be needed to achieve the goal of ‘single-hit’ gene therapy. Further, given our 
present lack of conclusive data regarding the identity of airway stem cells, a vector 
that could transduce cells irrespective of their level of turn-over, would be clearly 
advantageous. 
 
In contrast to retroviral vectors that can only transduce proliferating cells [8], 
lentiviruses are able to produce gene expression in non-dividing cells, including those 
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of the airway epithelium. However, to allow for receptor-mediated cell entry these 
vectors require pseudotyping to allow display of appropriate ligands for their cognate 
receptors. The most common pseudotyping, with glycoproteins of the vesicular 
stomatitis virus (VSVG), produces efficient transduction of a broad range of cells, and 
the virus can be readily concentrated and purified by high-speed centrifugation [9, 10]. 
However, they are not able to transduce airway epithelial cells in vivo when delivered 
via the apical surface. This, in turn, relates both to the difficulties such vectors have in 
penetrating the overlying mucus, and the lack of apically localized receptors on the 
epithelial cells [11-13]. Thus, the use of detergents such as lysophosphatidylcholine 
(LPC) or ethylene glycol bis(2-aminoethyl ether)-N,N,N'N'-tetraacetic acid (EGTA),  
help to breach these barriers, thereby allowing the vector to penetrate to the 
basolateral surface where the appropriate receptors reside. However, the suitability of 
such an approach in the bacteria-laden airways of CF patients is debatable. Thus, 
several groups have examined the use of a number of different pseudotyped lentiviral 
vectors for their airway epithelial transduction efficiency, including envelope 
glycoproteins of paramyxoviruses [14], filoviruses [15-17] and orthomyxoviruses [18]. 
Whilst encouraging data have been generated, we are not aware of a vector that 
fulfills the three key requirements of (1) efficient transduction of airway epithelial cells 
without the need for chemical pre-treatment, (2) long-term transgene expression and 
(3) the ability to be produced to high vector titres suitable for clinical application [19]. 
 
We describe here the development of a replication-defective lentiviral vector [20] 
derived from the simian immunodeficiency virus of the African green monkey (SIV) 
[21]. Using novel strategies we have been able to pseudotype this vector with the key 
Sendai virus envelope proteins, hemagglutinin-neuraminidase (HN) and fusion (F) 
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protein [14].  The HN and F proteins function respectively to attach to sialic acids, the 
receptor of SeV, and mediate cell fusion for vector entry to target cells. We have 
optimized vector production and transgene expression level of this F/HN-pseudotyped 
SIV vector by introducing the central polypurine tract (cPPT) [22] and the Woodchuck 
hepatitis virus posttranscriptional regulatory elements (WPRE) [23, 24]. We show that 
this F/HN-pseudotyped SIV vector can efficiently transduce nasal epithelial cells from 
the apical surface in vivo, resulting in transgene expression sustained for periods far 
beyond the proposed lifespan of airway epithelial cells. Importantly, we show that 
readministration is feasible. Finally, we demonstrate that this vector can transduce a 
fully differentiated human airway epithelium and that functional CFTR chloride 
channels can be generated after transduction with F/HN-SIV carrying the human 
CFTR cDNA in vitro. This vector may, therefore, be able to produce a step change in 
airway transduction efficiency relevant to a clinical programme of CF gene therapy. 
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RESULTS  
F/HN-pseudotyped SIV vectors can be generated and produced at high titres 
To accomplish pseudotyping of SIV vector with SeV envelope proteins, we have 
previously described that modifications of the F and HN proteins were needed [14]. 
Briefly, the cytoplasmic domain of the F protein was truncated to 4 amino acids, and 
the HN protein was fused with the cytoplasmic tail of the SIV transmembrane 
envelope protein. These modifications enabled the incorporation of F and HN-derived 
proteins into vector virions, generating an F/HN-pseudotyped SIV vector. 
 
We next constructed a series of gene transfer vectors in which the cPPT and/or 
WPRE were inserted into the parent gene transfer vector [20]. Their function was first 
evaluated using VSV-G pseudotyped SIV vectors encoding GFP. As expected, 
insertion of cPPT and WPRE increased vector production, from 3.8x106 TU/ml 
(cPPT-/WPRE-) to 1.4x107 TU/ml (cPPT+/WPRE-) and 6.7x106 TU/ml 
(cPPT-/WPRE+), respectively.  The insertion of both elements (cPPT+/WPRE+) led 
to the highest titre production (3.9x107 TU/ml). Because the number of particles 
produced in the supernatant (~2x108/ml) was similar in all cases, the introduction of 
these elements increased the quality of the vector by improving the TU to particle ratio 
from 1:100 to 1:10. Importantly, consistent with these data, insertion of these 
sequences into the SeV-F/HN-pseudotyped vectors encoding GFP increased virus 
production from 1x105 TU/ml (cPPT-/WPRE-) to 5x107 TU/ml (cPPT+/WPRE+), 
leading to an improvement in TU to particle ratio from 1:100 to 1:20. Thus, the 
cPPT/WPRE-containing vector was used in all subsequent experiments. The 
F/HN-pseudotyped SIV vector could be further concentrated from 2.0 ± 0.9x107 TU/ml 
to 6.1 ± 2.0x109 TU/ml (n=3) through centrifugation, making high titre use in vivo 
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feasible.  
 
F/HN-SIV-GFP transduces the nasal epithelium of mice  
We evaluated the in vivo gene transduction efficiency of the SeV-F/HN-pseudotyped 
SIV vector in the nasal airway epithelium of mice. This tissue was chosen because the 
characteristic pathophysiological abnormalities of CF are reproduced in the nasal, but 
not the lower airways of CF knockout mice. In addition, in contrast to the murine lung, 
cell composition in the murine nasal epithelium is more akin to the human lung and 
contains both submucosal glands, as well as mucous-secreting cells, thereby allowing 
evaluation of whether the vector is able to penetrate a mucus-enriched airway surface 
fluid layer. As part of this study approximately 100 mice were treated (for details see 
individual Figure legends). The overall survival over the course of the >15 months 
study was 100%. 
 
To examine transduction efficiency of respiratory epithelial cells, we administered 
F/HN-pseudotyped SIV vector encoding GFP to the nose of mice at a dose of 4x108 
TU/mouse. Thirty days after transfection, GFP positive respiratory epithelial cells were 
identified and quantified on histological sections collected 1 to 4 mm from the tip of the 
nasal bone (Figure 1). Transduction efficiency along the nasal septum was 4.5 ± 
0.7% (mean ± SEM, n=8). This corresponds favorably with the approximately 5% of 
cells estimated to require transduction for generating clinical benefit.  
 
F/HN-SIV transduces cells in both the respiratory and olfactory epithelium 
Using high power microscopic analysis we were able directly to detect and identify 
GFP fluorescent cells 30 days after transfection. The murine nasal epithelium consists 
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of squamous cells in the anterior part of the nose, changing to respiratory epithelium 
in the mid-portion and neuroepithelial olfactory epithelium in the dorsoposterior 
regions [25]. The majority (approximately 69%) of GFP positive cells were ciliated 
respiratory epithelial cells (Figure 2A) followed by neuronal cells (21%) in the 
olfactory epithelium (Figure 2B) and squamous cells (7%) (Figure 2C). The number 
of neuronal cells transduced was very few in the anterior part of the nose and 
increased in the posterior region as expected. The remainder (3%) were mainly 
non-neuronal cells in the olfactory epithelium, most likely sustentacular cells (Figure 
2D), a major constituent of the olfactory epithelium. Interestingly, we did not detect 
GFP-expressing goblet cells, a cell type commonly transduced in VSGV-SIV perfused 
LPC-pre-conditioned nasal epithelium (data not shown). 
 
GFP expression persists for more than 1 year after F/HN-SIV-GFP transduction  
To determine the duration of gene expression mice were perfused with 
F/HN-SIV-GFP (4x108 TU/mouse) or PBS and harvested 3 to 449 days after 
transfection (Figure 3A+B). F/HN-SIV-mediated GFP expression was visible in the 
nasal cavity using in situ imaging as early as 10 days post transduction and was still 
detectable in 7 out of 10 and 3 out of 10 mice 360 and 449 days after a single 
administration of the vector, respectively. At this time-point GFP positive cells 
appeared to be randomly distributed within the tissue similar to the distribution 
observed 30 days after transfection (Figure 3C). GFP was undetectable in 
LPC-preconditoned VSVG-SIV-GFP transduced tissue (data not shown). Histological 
sections were used to quantify the number of GFP positive cells over time. As a whole, 
the number of GFP positive cells gradually declined over time by approximately 70% 
(Figure 3D). In some mice marked decline of GFP positive cells were observed after 
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90 days post-transduction, however, in the other mice the number of transduced cells 
were maintained well even at 360 days post-transduction to the similar level of that at 
30 days post-transduction. In addition, it is important to note that GFP positive cells 
were still detectable in 16 out of 17 mice 12 months after transduction.  
 
We also used in vivo bioluminescence imaging after nasal perfusion with 
F/HN-SIV-Lux to assess gene expression over time in the same animal (Figure 3E).  
Figure 3F shows quantification of photon emission after intraperitoneal injection of 
luciferin substrate from one to eight months after transduction. Although persistence 
of gene expression far exceeds the expected life-span of airway epithelial cells of 100 
days, possibly indicating progenitor cell integration, repeated bioluminescence in vivo 
imaging (BLI) after F/HN-SIV-lux transduction shows a gradual decline in photon 
emission over a 8 months period (month 1: 2.2x106 ± 4.9x105, month 8: 2.7x105 ± 
8.8x104, n=10/group, p<0.005), but was still significantly (p<0.01) higher than the PBS 
control (4.5x104±2.0x103, n=5)  This result is consistent with the decline in GFP 
positive cells described above. In addition we analyzed all data using a repeat 
measure test to determine if the decline in bioluminescence stabilizes during the 8 
months study period. The analysis showed that gene expression significantly (p<0.05) 
declined for the first 4 months but then stabilized with expression levels from 5 to 8 
months not being different compared to the 4 months levels.     
 
The SIV vector-transduced cells show clustering after induced regeneration of 
the epithelium 
To ascertain further whether F/HN-SIV induced chromosomal integration into nasal 
respiratory progenitor or stem cells, we artificially induced cell division after SIV vector 
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transduction by damaging the nasal tissue with the detergent (polidocanol) [6], which 
has previously been shown to strip the surface epithelium within a few hours, while 
retaining basal cells able to regenerate the epithelium within 7 days (Figures 4A-D).  
Seven and 28 days after vector transduction (4x108 TU/mouse, n=3) the nasal tissue 
was perfused with 2% polidocanol (10 µl/mouse) and gene expression analyzed 4 
weeks after the last detergent treatment. Importantly, GFP-expressing cells now 
showed clustering after polidocanol treatment (Figure 4E and supplementary 
Figure S2), possibly indicating origination from a common progenitor.  
 
SIV-mediated gene transfer can be achieved after three applications of the 
vector 
Whilst the above data are encouraging, gene therapy for CF will require life-long 
treatment. We therefore, assessed the feasibility of readministering this vector, and 
compared transduction efficiency to the current optimal non-viral formulation for 
airway gene transfer in vivo. Figure 5 shows that following two administrations of 
F/HN-SIV-GFP separated by one month, a third administration of F/HN-SIV-lux (to 
prevent an immune response against the transgene) produced gene expression of 
approximately 40% of that seen following a single challenge with F/HN-SIV-lux. 
Further, these levels after three challenges with the SIV vector remained 
approximately 500-fold greater (p<0.01) than seen with an optimal non-viral 
formulation, previously used in a CF clinical trial. 
 
F/HN-SIV transduces differentiated human airway epithelium 
Differentiated human airway epithelium is in general difficult to transduce. In 
preliminary experiments we have shown that F/HN-pseudotyped lentivirus transduced 
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human airway cells grown as air-liquid interphase (ALI) cultures. ALIs were 
transfected with F/HN-SIV carrying a luciferase reporter gene at an approximate MOI 
of 100 and luciferase expression was detectable 10 and 26 days after gene transfer 
(day 10: 53.0 ± 6.3 RLU/mg protein, day 26: 7.9 ± 3.4 RLU/mg protein, untransfected: 
0.01 RLU/mg protein, n=3/group) and Figure 6. Importantly, gene transfer occurred 
without the need for pre-conditioning.   
 
Transduction with F/HN-SIV carrying the CFTR cDNA leads to expression of 
cAMP-dependent chloride channels  
Iodide efflux is commonly used to demonstrate the presence of forskolin-activated 
chloride channels in vitro. In this assay iodide is used as a surrogate for chloride due 
to the shorter half-life of the radioactive material. We have constructed a F/HN-SIV 
carrying a GFP-CFTR fusion cDNA construct and transduced HEK293T cells to 
assess whether functional CFTR chloride channels are generated. Fusion of GFP to 
the N-terminus of CFTR has previously been shown not to effect CFTR function [26, 
27]. Figure 7 shows that cells transduced with F/HN-SIV-GFP-CFTR (MOI 50) 
significantly (p<0.001) increased cAMP-mediated efflux compared to cells treated with 
a F/HN-SIV-GFP control virus. We, therefore, conclude that transduction with 
F/HN-SIV-GFP-CFTR generates functional CFTR chloride channels in vitro. 
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DISCUSSION  
Here we show that a) we can produce titres of a novel SIV vector pseudotyped with 
Sendai virus envelope proteins appropriate for in vivo use, b) the vector can transduce 
the respiratory epithelium of the murine nose in vivo at levels that may be relevant for 
clinical benefit in CF, as previously suggested by in vitro mixing experiments [28], c) 
this can be achieved in a single formulation, and without the need for preconditioning, 
d) expression can last for at least half the lifespan of a mouse, e) the vector can 
produce levels of gene expression approximately 500-fold greater than the current 
optimal non-viral formulation after three repeated administrations, f) the vector is able 
to transduce a fully differentiated human airway epithelium and g) can produce 
functional cAMP-dependent CFTR chloride channels in vitro. 
 
We inserted cPPT and WPRE sequences into the SIV vector. Both elements have 
previously been reported to increase gene transduction efficiency possibly due to 
acceleration of the movement of the pre-integration complex of the vector into the 
nucleus [22, 29, 30], or other mechanisms [23, 31]. Interestingly, a synergistic effect of 
these two elements has been observed for HIV-based lentiviral vectors [24]. Our data 
are in keeping with these observations, with simultaneous insertion of cPPT and 
WPRE increasing productivity of both the VSVG and SeV-F/HN-pseudotyped SIV 
vectors. Using these methods we were able to reach titers of the 
SeV-F/HN-pseudotyped SIV vector of 5x107 TU/ml. Thus, this vector may be able to 
overcome one previously encountered important translational hurdle.  
 
Lentiviral vectors pseudotyped with a variety of envelope proteins other than VSV-G 
have been described, including those from Ebola, Zaire [15, 16], influenza 
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hemagglutinin (HA) from fowl plague virus [18] and baculovirus GP64 envelopes [17]. 
Amongst these, arguably it is the transduction efficiency of the baculovirus 
GP64-pseudotyped vectors which is most impressive, when applied in a viscoelastic 
gel formulation (1% methylcellulose) as a vector solvent. However, the regulatory 
complexities of moving two new agents into the clinic simultaneously, underline the 
encouraging transduction efficiency and duration we report here without the need for 
additions to the formulation. 
 
The likely target for CF gene therapy are the ciliated epithelial cells, and more than 
70% of the cells transduced by the F/HN SIV vector were of this type. This is in 
keeping with transduction of these cells by the ‘parent’ SeV vector, and overcomes a 
second hurdle in the translation of these vectors towards the clinic. The number of 
cells requiring transduction for clinical benefit is a vexed, and unresolved question. In 
part this may depend on which of the many functions of CFTR requires correction. 
Thus, if the chloride channel function predominates, in vitro data suggest that as few 
as 5% of cells may be sufficient [32]. These values are in reach of the F/HN SIV vector 
described here.  
 
Using a human cytomegalovirus (CMV) promoter we saw expression of GFP for more 
than 360 days in 16 out of 17 mice, although gene expression gradually decreased 
over time when quantified as number of cells expressing the GFP reporter gene or 
longitudinal assessment of bioluminescent imaging. The onset of transgene 
expression was typically delayed, with no GFP fluorescence detected at day 3, but 
clearly visible by day 10. This has also been reported for an Ebola virus Z protein 
(EboZ)-pseudotyped HIV vector [15]. Possible explanations include the delayed 
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movement of the pre-integration complex to the nucleus, or the shutting off of 
promoter activity by concomitant inflammation consequent upon transduction [33, 34], 
with subsequent expression following the resolution of inflammation. Irrespective, 
transgene expression was still apparent up to 449 days after transduction the longest 
timepoint assessed. Because the life span of terminally differentiated airway epithelial 
cells has been estimated at around 90 days [6], both in mice and in man, we 
considered whether this vector may have transduced progenitor or stem cells within 
the airway epithelium. We would predict that in this case we would observe clonal 
expansion, with clustering of transgene positive cells, and this was seen following 
induced regeneration of epithelial cells after polidocanol treatment. Cells derived from 
progenitor or stem cells thought to reside near the basement membrane, have 
previously been shown to move laterally during differentiation [35]. Thus, in the 
absence of epithelial damage, SIV vector-transduced progenitor or stem cell-derived 
cells should be observed in a scattered pattern without clustering (see schematic 
presentation in Figure 8A). In contrast, following epithelial stripping, a different 
pattern would be predicted to occur, with clusters of transduced cells becoming visible 
(see schematic presentation in Figure 8B). This hypothesis may explain, why we 
observed clusters of GFP positive cells in damaged but not in undamaged epithelium. 
However, more extensive studies will be necessary to understand and more 
conclusively prove stem or progenitor cell transduction. Other explanations for the 
unexpectedly long duration of expression include (1) an alteration in the cell cycle of 
transduced respiratory epithelial cells, although to our knowledge this has not 
previously been reported, (2) expression from -resident airway inflammatory or 
immune cells, for which we saw no evidence or (3) a longer than 3 months half-life of 
respiratory epithelial cells, which has recently been suggested by Rawlins et al [36]. 
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The treatment of CF will require lifelong expression of the normal CFTR protein. Thus, 
despite these encouraging data showing long-lasting expression from a single 
administration, we assessed whether repeated application of this vector could sustain 
gene expression.  We show that repeated mucosal administration of F/HN 
pseudotyped lentivirus, when given monthly over a 3 months period, is feasible and 
led to gene expression approximately 40% of that seen following a single 
administration. This dosing interval may be of subsequent clinical relevance. Sinn et 
al [36] have recently shown that seven weekly administrations of a 
GP64-pseudotyped FIV given in tandem with a ciliastatic agent, are able to produce 
repeatable expression. Further, each study was undertaken in a different inbred 
mouse strain. The significant differences between the studies, yet with similar 
outcome, provide a growing body of evidence that such vectors can be 
readministered.  
 
Differentiated human airway epithelium is in general difficult to transduce. However, 
we have shown here that F/HN-SIV transduced fully differentiated human airway 
epithelium successfully, and that reporter gene expression could be detected for at 
least 26 days after transduction. Importantly, gene transfer occurred without the need 
for pre-conditioning with tight junction openers or cilia static agents that are often 
required with other viral vectors. This provides encouraging support for its use in 
human trial.  
 
In addition to demonstrating that F/HN-SIV carrying the CFTR cDNA was able to 
generate cAMP-dependent chloride channels in vitro, we also attempted to correct 
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nasal potential difference in CF knockout mice. However, we did not detect any 
changes in ion transport (data not shown). Importantly, the suitability of the CF mouse 
nasal epithelium as a model has been put into question by two recent publications 
showing that the nasal bioelectrics are dominated by the olfactory rather than the 
respiratory epithelium [37, 38]. Our experience is in keeping with this observation. 
Transduction with Sendai virus, which transduces respiratory and olfactory epithelium 
led to significant increases in chloride transport [39], whereas lentivirus and non-viral 
gene transfer agents (unpublished data), which predominantly transduce ciliated 
respiratory epithelial cells were unable to alter ion transport in the mouse nose. Until 
more appropriate animal models become widely available, analysis of CFTR function 
after gene transfer may, for certain gene transfer agents, be restricted to in vitro 
models. 
 
 
Clearly, at least one remaining crucial hurdle is the risk-benefit ratio of these 
integrating vectors. The cases of leukemia in the SCID trial using a retroviral vector 
have been well documented, but lentiviral vectors are considered by many to be less 
susceptible to these problems. Further, the slowly dividing airway epithelium may 
represent a very different risk to the rapid turnover of bone marrow stem cells. 
Encouragingly, in our study of approximately 100 mice, over a one year period we 
saw no adverse events attributable to the vector. However, the encouraging increase 
in median survival of CF patients to the current approximately 36 years suggests that 
extensive toxicology studies will be needed before clinical trials can begin. 
 
In conclusion, we suggest that the SeV-F/HN-pseudotyped SIV vector reported here 
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may represent a further step towards translating such integrating viral vectors into 
clinical use. Several key hurdles have been potentially overcome, pushing these 
vectors into the arena as candidates for clinical trials. 
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MATERIALS AND METHODS 
Cell culture. Human embryonic kidney 293T and 293T/17 cells (CRL-11268, ATCC, 
Manassas, VA) were maintained in Dulbecco’s minimal Eagle’s medium (Invitrogen, 
Carlsbad, CA) containing 10% fetal bovine serum and supplemented with penicillin 
(100 U/ml) and streptomycin (100 µg/ml). 
 
Plasmid Construction. pCAGGS-Fct4 and pCAGGS-SIVct+HN were constructed as 
previously described [14]. The cPPT and WPRE sequences [40] were inserted in the 
SIV-derived gene transfer plasmid [21].  
 
Production of SIV vector. Replication-defective self-inactivating SIV vector was 
constructed as previously described [20] with minor modifications. Briefly, the 
SeV-F/HN-pseudotyped SIV vector was produced by transfecting 293T/17 cells (15 
cm diameter culture dishes) with four plasmids complexed to Lipofectamine/Plus 
reagents (Invitrogen, Carlsbad, CA) according to the manufacturer’s 
recommendations [Plasmid-1: 10 µg SIV-derived transfer plasmid carrying a green 
fluorescent protein (GFP), a luciferase (lux) reporter gene or a GFP-CFTR fusion 
construct [26], Plasmid-2: 3 µg packaging plasmid, Plasmid-3: 2 µg pCAGGS-Fct4, 
Plasmid 4: 2 µg pCAGGS-SIVct+HN]. The VSV-G pseudotyped SIV vector was 
produced using a similar protocol, but a pVSV-G plasmid (2 µg, Clontech, Mountain 
View, CA) was used instead of pCAGGS-Fct4 and pCAGGS-SIVct+HN. Twelve hours 
after transfection the culture medium was replaced with 30 ml serum-free DMEM 
containing 5 mM sodium butyrate. Sodium butyrate stimulates the vector production to 
inhibit histone deacetylase [41, 42]. The culture supernatant containing the SIV vector 
was harvested 48 hours after transfection, filtered through a 0.45 µm filter membrane 
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and further concentrated by high-speed centrifugation (20,000 g for 4 hours at 4°C, 
Beckman Avanti JA18 rotor). The vector pellets were suspended in 
phosphate-buffered saline (PBS) (Invitrogen, Carlsbad, CA) to 100 ~ 200-fold 
concentration and stored at –80°C. 
 
Vector titration. The particle titer was determined using real-time RT-PCR. Virus 
RNA was purified using a QIAamp viral RNA mini-kit (QIAGEN, Strasse, Germany), 
and reverse transcribed using Superscript II (Invitrogen, Carlsbad, CA). The 
QuantiTect probe PCR system (QIAGEN, Strasse, Germany) and primers for 
amplifying 131 nucleotides (bp) spanning the WPRE sequence (forward primer: 
5’-ggatacgctgctttaatgcc-3’, reverse primer: 5’-acgccacgttgcctgacaac-3’) were used 
according to the manufacturer’s protocol in an ABI PRISM 7700 Sequence Detector 
System (PE Applied Biosystems, Foster City, CA). SIV gene transfer plasmid DNA 
(3x104 to 2x106 molecules) was used as standard.  
 
Transduction units (TU/ml) were determined by transducing 293T cells with serial 
dilutions of vector stock and quantification of tranduced cells by GFP fluorescence (for 
F/HN-SIV-GFP and VSVG-SIV-GFP) or staining with anti-luciferase antibody (for 
F/HN-SIV-lux). To work with a consistent virus concentration throughout the study 
virus stocks were all adjusted to a final volume of 4x109 TU/ml. A titre of 4x109 TU/ml 
was used for all animal studies.  
 
In vivo administration to the mouse nose. All animal studies had been approved by 
the DNAVEC Animal Care Committee and the Imperial College Animal Ethics 
Committee and were carried out according to Home Office regulations. C57BL/6N 
Mitomo et al. 
21 
mice (female, 6-8 weeks) were used. Mice were anesthetized, placed horizontally on 
their backs onto a heated board and a thin catheter (<0.5 mm outer diameter) was 
inserted approximately 2.5 mm from the tip of nose into the left nostril. Using a syringe 
pump (Cole-Palmer, Illinois, USA) vector (100 μl) was then slowly perfused onto the 
nasal epithelium (1.3 μl/min) for 75 min. Despite, perfusion of virus into the left nostril, 
we routinely observe transfection in both left and right nostrils, which is due to 
dispersion of the solutions throughout the entire nasal cavity. PBS and VSVG-SIV 
transduced mice preconditioned with 1% lysophosphatidylcholine (LPC) as described 
by Limberis et al were used as controls [43]. At indicated time-points (3 to 360 days 
after transduction) mice were culled to visualize GFP expression.  
 
In the repeat administration experiments groups of mice were transduced with either 
one dose of F/HN-SIV-lux (single dose group), or two doses of F/HN-SIV-GFP (day 0, 
day 28), followed by F/HN-SIV-lux on day 56 (repeat dose group). Importantly, mice 
receiving F/HN-SIV-lux (single dose group) and F/HN-SIV-lux on day 56 (repeat dose 
group) were of similar age and were transduced at the same time. Gene expression 
was analyzed 30 days after F/HN-SIV-lux administration. For comparison mice were 
transfected with the cationic lipid GL67A complexed to a luciferase reporter gene as 
previously described [44] and luciferase expression was measured 2 days after 
transfection.  
 
Induced regeneration of nasal epithelial cells by polidocanol treatment. Nasal 
epithelial cells were stripped by polidocanol treatment according to the method 
described by Borthwick et al [6] with some modification. In brief, mice were 
anaesthetized and 10 µl Polidocanol (2%) were administered to the nose as a bolus 
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by “nasal sniffing”. To confirm the stripping and regeneration of nasal epithelial cells, 
nasal tissue was perfused with 10 µl of 2% (v/v in PBS) polidocanol (Nonaethylene 
glycol mono-dodecyl ether, SIGMA, St. Louis, MO) and histological analysis 
undertaken 24 hours and 7 days after treatment (n=3 per group). To analyze 
transduction of possible progenitor or stem cells, we first administered F/HN-SIV-GFP 
(4 x 108 TU/mouse) vector to mouse nasal epithelium. Seven days after transduction, 
nasal tissue was perfused with 10 µl of 2% (v/v in PBS) polidocanol, and this 
treatment was repeated again 3 weeks later. Histological sections were analyzed 58 
days after vector administration (30 days after the last polidocanol treatment). 
 
Bioluminescent imaging. Mice were injected intraperitoneally with 150 mg/kg of 
D-Luciferin (Xenogen Corporation, Alameda, CA) 10 min before imaging and were 
anaesthetised with isofluorane. Bioluminescence (photons s-1 cm-2 sr-1) from living 
mice was measured using an IVIS50 system (Xenogen Corporation) at a binning of 4 
for 10 minutes, using the software programme Living Image (Xenogen). For 
anatomical localisation a pseudocolour image representing light intensity (blue least 
intense, red most intense) was generated using Living Image software and 
superimposed over the greyscale reference image. To quantify bioluminescence in 
the nose photon emission in a defined area (red box) was measured by marking a 
standardized area for quantification. The size of the red box was kept constant and 
was placed over the heads of the animals as indicated in the Figure. Importantly the 
areas were marked using the greyscale reference image to avoid bias.  
 
Tissue preparation for histological assessment of GFP expression. Mice were 
culled and the skin was removed. The head was cut at eye level and skin, jaw, tongue 
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and the soft tip of the nose were carefully removed. For in situ imaging of GFP 
expression in the nasal cavity, GFP fluorescence was detected using fluorescence 
stereoscopic microscopy (Leica, Ernst Leitz Optische Werke, Germany). 
Subsequently, the tissue was fixed in 4% paraformaldehyde (pH 7.4) overnight at 
room temperature and was then submerged in 20% EDTA (pH 7.5 for 5 days) for 
decalcification. The EDTA solution was changed at least every second day. After 
decalcification the tissue was incubated in 15% sucrose overnight at room 
temperature and was then embedded in Tissue Mount (Chiba Medical, Soka, Saitama, 
Japan). Ten µm sections were cut at 6 different positions in each mouse head 
(approximately 0 to 6 mm from the tip of nasal bone). GFP expression was observed 
using a fluorescent microscope (Leica, Ernst Leitz Optische Werke, Germany). 
Quantification and identification of cell types was carried out on 6 levels/mouse using 
a 40x or 63x objective. Prolonged image exposure was necessary to capture the 
structure of the nasal epithelium using fluorescent microscopy. This led to pixel 
saturation of GFP positive cells and causes GFP positive cells to appear almost white 
rather than the common green appearance that we, and others, observe under higher 
magnification. 
 
Transduction of air-liquid interphase cultures. Fully differentiated airway epithelial 
cells grown as air-liquid interphase (ALIs) cultures were purchased from Epithelix 
(Geneva, Switzerland). ALIs were transfected with F/HN-SIV-Lux at an MOI ranging 
from approximately 25 to approximately 300. The virus was dissolved in 50 μl PBS 
and applied to the apical surface. After 6 hrs the virus was removed and ALIs were 
incubated for 10 to 26 days. The basolateral medium was changed every 48 hrs 
during this incubation period. At specified time-points the ALIs were lysed in 100 µl 
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RLB buffer and luciferase expression was quantified using the Luciferase Assay 
System (Promega, Southampton, UK) according to the manufacturer’s instructions. 
The total protein content of the cultures was quantified using the BioRad protein assay 
kit (BioRad, Hemel Hempstead, UK). Each sample was assayed in duplicate. 
Luciferase expression was then presented as Relative Light Units (RLU)/ mg total 
protein. For bioluminescence imaging 100 μg luciferin in PBS were added to the 
apical membrane . 
 
Iodide efflux assay. HEK293T cells were transfected with F/HN-SIV-GFP-CFTR or a 
F/HN-SIV-GFP control virus at an MOI of 500 and cultured for 2 days. CFTR chloride 
channel activity was assayed by measuring the rate of 125iodide efflux as previously 
described [45].  The 125iodide efflux rates were normalized to the time of 
forskolin/IBMX addition (time 0). Curves were constructed by plotting rates of 125iodide 
efflux against time. To reflect the cumulative levels of 125iodide efflux following 
agonist-stimulation, all comparisons are based on areas under the time-125iodide 
efflux curves. The area under the curve was calculated by the trapezium rule. 
Experiments were carried out in duplicate (n=6 wells/group/experiment) 
 
Statistical analysis. Normal distribution was assessed for all data and parametric or 
non-parametric statistical analysis was performed as appropriate. Data in Figure 3f 
were analyzed using the Mann-Whitney U-test to compare bioluminescence at month 
1 and 8, as appropriate for non-parametric data. In 2 out 10 mice bioluminescence 
had returned to baseline levels before month 8 and these mice did not undergo 
additional BLI. For the final quantification of gene expression at 8 months the mean 
bioluminescence of the PBS control cohort was used for these 2 mice. In addition data 
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in Figure 3f was analyzed using a Friedman repeat measure test followed by Dunn’s 
multiple comparison post-hoc test, as appropriate for non-parametric data.      
Data in Figure 5 was analyzed by Kruskal-Wallis followed by Dunn’s Multiple 
Comparison test, as appropriate for non-parametric data. Data in Figure 6 were 
analyzed by ANOVA followed by Bonferroni’s Multiple Comparison Post-hoc test, as 
appropriate for normal distributed data. The null hypothesis was rejected at p<0.05. 
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The murine nose was perfused in vivo with F/HN-SIV-GFP (4x108 TU/mouse) vector 
and gene expression analyzed 30 days after transduction (n=8). Top panels: In situ 
imaging of GFP expression in the nasal cavity. Bottom panel: Microscopic imaging of 
GFP in histological sections. The sections were collected (A) 1 mm, (B) 2 mm, (C) 3 
mm and (D) 4 mm into the nasal tissue (vertical white lines). GFP positive cells appear 
as small white punctuate signals. 
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gene expression was analyzed at indicated time-points after transduction. (A) 
Representative in situ images of GFP expression in the nasal cavity from mice 
analyzed 3 to 449 days after transduction. (B) In situ imaging of GFP expression in 
the nasal cavity from 10 mice analyzed 360 days after transduction. (C) 
Representative microscopic images of GFP expression in histological sections 360 
and 449 days after transduction. GFP positive cells appear as small white punctuate 
signals. (D) Quantification of transduced cells. GFP positive cells were quantified on 
histological sections taken 2 mm into the nasal tissue of the nose. Data from 30 to 360 
days after transduction are represented both by mean±SEM and individual values 
(ratio to GFP cells positive on day 30). The n number per group are 13 (day 30), 3 
(day 50), 12 (day 90), 14 (day 160-180), 10 (day 220-270) and 17 (day 360). (E) 
Biolumiescence in vivo imaging one (1 M) to eight months (8 M) after transduction 
with F/HN-SIV-lux. Representative images of 2 out of 6 mice are shown. Red box 
indicates area chosen for quantification of photon emission. (F) Quantification of in 
vivo bioluminescence over time after transduction with F/HN-SIV-lux (black lines) or 
PBS (red lines). Each line represents photon emission over time in one animal. *** = 
p<0.005 compared to bioluminescence one month after gene transfer. 
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transduction with F/HN-SIV vector (E). Seven days after transduction of nasal 
epithelial cells with F/HN-SIV-GFP (4x108 TU/100 μl/mouse), the nasal epithelium 
was stripped via perfusion with 10 µl of 2% (v/v) polidocanol. Polidocanol treatment 
was repeated again 3 weeks later. Histological sections were analyzed 58 days after 
vector administration (30 days after the last polidocanol treatment). In situ imaging of 
GFP expression in the nasal cavity of untreated mice (top panel in E) or mice treated 
with polidocanol (bottom panel in E). Clusters of GFP positive cells were seen in the 
polidocanol treated mice.  
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Figure 6: Transduction of human air-liquid interface (ALIs) cultures with 
F/HN-SIV-lux 
ALIs were transduced with F/HN-SIV-lux at an approximate MOI of 25 (1-3) and 250 
(4-6) or treated with PBS (7-9). 5 days after transduction ALIs were treated with 
luciferin and biolumescent imaging performed.    
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